Cargando…
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the interv...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362210/ https://www.ncbi.nlm.nih.gov/pubmed/28328980 http://dx.doi.org/10.1371/journal.pone.0173440 |
_version_ | 1782516921542901760 |
---|---|
author | Plomgaard, Anne M. Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hyttel-Sorensen, Simon Lemmers, Petra van Oeveren, Wim Pellicer, Adelina Petersen, Tue H. Pichler, Gerhard Winkel, Per Greisen, Gorm |
author_facet | Plomgaard, Anne M. Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hyttel-Sorensen, Simon Lemmers, Petra van Oeveren, Wim Pellicer, Adelina Petersen, Tue H. Pichler, Gerhard Winkel, Per Greisen, Gorm |
author_sort | Plomgaard, Anne M. |
collection | PubMed |
description | BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the intervention and the control group. The primary outcome was the reduction in the burden of cerebral hypo- and hyperoxia between the two groups. In this study we describe the associations between the burden of cerebral hypo- and hyperoxia, regardless of allocation to intervention or control group, and the biomarkers of brain injury from birth till term equivalent age that was collected as secondary and explorative outcomes in the SafeBoosC II trial. METHODS: Cerebral oxygenation was continuously monitored during the first 72h of life in 166 extremely preterm infants. Cranial ultrasound was performed at day 1,4,7,14, and 35 and at term. Electroencephalogram (EEG) was recorded at 64h. Blood-samples taken at 6 and 64 hours were analysed for the brain injury biomarkers; S100beta, brain-fatty-acid-binding-protein, and neuroketal. All analyses were conducted post hoc. RESULTS: Significantly more infants with a cerebral burden of hypoxia within the 4(th) quartile versus infants within quartile 1–3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia. The blood biomarkers were not significantly associated with the burden of cerebral hypo- or hyperoxia. CONCLUSIONS: The explorative analysis showed that early burden of cerebral hypoxia, but not hyperoxia was significantly associated with low brain electrical activity and severe intracranial haemorrhage while none of the three blood biomarkers were associated with the burden of either cerebral hypo- or hyperoxia. |
format | Online Article Text |
id | pubmed-5362210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-53622102017-04-06 Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial Plomgaard, Anne M. Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hyttel-Sorensen, Simon Lemmers, Petra van Oeveren, Wim Pellicer, Adelina Petersen, Tue H. Pichler, Gerhard Winkel, Per Greisen, Gorm PLoS One Research Article BACKGROUND: The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxygenation by near-infrared spectroscopy combined with a guideline on treatment when cerebral oxygenation was out of the target range. Data on cerebral oxygenation was collected in both the intervention and the control group. The primary outcome was the reduction in the burden of cerebral hypo- and hyperoxia between the two groups. In this study we describe the associations between the burden of cerebral hypo- and hyperoxia, regardless of allocation to intervention or control group, and the biomarkers of brain injury from birth till term equivalent age that was collected as secondary and explorative outcomes in the SafeBoosC II trial. METHODS: Cerebral oxygenation was continuously monitored during the first 72h of life in 166 extremely preterm infants. Cranial ultrasound was performed at day 1,4,7,14, and 35 and at term. Electroencephalogram (EEG) was recorded at 64h. Blood-samples taken at 6 and 64 hours were analysed for the brain injury biomarkers; S100beta, brain-fatty-acid-binding-protein, and neuroketal. All analyses were conducted post hoc. RESULTS: Significantly more infants with a cerebral burden of hypoxia within the 4(th) quartile versus infants within quartile 1–3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia. The blood biomarkers were not significantly associated with the burden of cerebral hypo- or hyperoxia. CONCLUSIONS: The explorative analysis showed that early burden of cerebral hypoxia, but not hyperoxia was significantly associated with low brain electrical activity and severe intracranial haemorrhage while none of the three blood biomarkers were associated with the burden of either cerebral hypo- or hyperoxia. Public Library of Science 2017-03-22 /pmc/articles/PMC5362210/ /pubmed/28328980 http://dx.doi.org/10.1371/journal.pone.0173440 Text en © 2017 Plomgaard et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Plomgaard, Anne M. Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hyttel-Sorensen, Simon Lemmers, Petra van Oeveren, Wim Pellicer, Adelina Petersen, Tue H. Pichler, Gerhard Winkel, Per Greisen, Gorm Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title | Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title_full | Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title_fullStr | Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title_full_unstemmed | Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title_short | Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial |
title_sort | early biomarkers of brain injury and cerebral hypo- and hyperoxia in the safeboosc ii trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362210/ https://www.ncbi.nlm.nih.gov/pubmed/28328980 http://dx.doi.org/10.1371/journal.pone.0173440 |
work_keys_str_mv | AT plomgaardannem earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT alderliestenthomas earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT austintopun earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT vanbelfrank earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT bendersmanon earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT clarisolivier earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT dempseyeugene earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT fumagallimonica earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT gluudchristian earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT hagmanncornelia earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT hyttelsorensensimon earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT lemmerspetra earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT vanoeverenwim earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT pelliceradelina earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT petersentueh earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT pichlergerhard earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT winkelper earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial AT greisengorm earlybiomarkersofbraininjuryandcerebralhypoandhyperoxiainthesafeboosciitrial |